Cargando…
Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
Clinical and psychosocial deterioration associated with schizophrenia occurs within the first few years following the onset of the illness. Therefore, to improve the long-term prognosis, it is important to provide schizophrenia patients with intensive treatment following their first episode. Relapse...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425805/ https://www.ncbi.nlm.nih.gov/pubmed/22966439 http://dx.doi.org/10.1155/2012/560836 |
_version_ | 1782241420694781952 |
---|---|
author | Kim, Borah Lee, Sang-Hyuk Yang, Yen Kuang Park, Jong-Il Chung, Young-Chul |
author_facet | Kim, Borah Lee, Sang-Hyuk Yang, Yen Kuang Park, Jong-Il Chung, Young-Chul |
author_sort | Kim, Borah |
collection | PubMed |
description | Clinical and psychosocial deterioration associated with schizophrenia occurs within the first few years following the onset of the illness. Therefore, to improve the long-term prognosis, it is important to provide schizophrenia patients with intensive treatment following their first episode. Relapse is highly associated with partial medication adherence or nonadherence in patients with first-episode schizophrenia. Recent studies suggest that long-acting injectable (LAI) antipsychotics compared with oral antipsychotics are more effective for medication adherence and relapse prevention. Moreover, some clinical guidelines for the treatment of schizophrenia suggested that LAI antipsychotics should be considered when patients are nonadherent “at any stage.” Decreased compliance is a common cause of relapse during the initial stages of the disease. Therefore, LAI antipsychotics should be highly considered when treating patients with first-episode schizophrenia. In the present paper, clinical trial data and current guidelines on the use of LAI antipsychotics for first-episode schizophrenia are discussed as well as the pros and cons of this treatment option. |
format | Online Article Text |
id | pubmed-3425805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-34258052012-09-10 Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons Kim, Borah Lee, Sang-Hyuk Yang, Yen Kuang Park, Jong-Il Chung, Young-Chul Schizophr Res Treatment Review Article Clinical and psychosocial deterioration associated with schizophrenia occurs within the first few years following the onset of the illness. Therefore, to improve the long-term prognosis, it is important to provide schizophrenia patients with intensive treatment following their first episode. Relapse is highly associated with partial medication adherence or nonadherence in patients with first-episode schizophrenia. Recent studies suggest that long-acting injectable (LAI) antipsychotics compared with oral antipsychotics are more effective for medication adherence and relapse prevention. Moreover, some clinical guidelines for the treatment of schizophrenia suggested that LAI antipsychotics should be considered when patients are nonadherent “at any stage.” Decreased compliance is a common cause of relapse during the initial stages of the disease. Therefore, LAI antipsychotics should be highly considered when treating patients with first-episode schizophrenia. In the present paper, clinical trial data and current guidelines on the use of LAI antipsychotics for first-episode schizophrenia are discussed as well as the pros and cons of this treatment option. Hindawi Publishing Corporation 2012 2012-08-14 /pmc/articles/PMC3425805/ /pubmed/22966439 http://dx.doi.org/10.1155/2012/560836 Text en Copyright © 2012 Borah Kim et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Kim, Borah Lee, Sang-Hyuk Yang, Yen Kuang Park, Jong-Il Chung, Young-Chul Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons |
title | Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons |
title_full | Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons |
title_fullStr | Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons |
title_full_unstemmed | Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons |
title_short | Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons |
title_sort | long-acting injectable antipsychotics for first-episode schizophrenia: the pros and cons |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425805/ https://www.ncbi.nlm.nih.gov/pubmed/22966439 http://dx.doi.org/10.1155/2012/560836 |
work_keys_str_mv | AT kimborah longactinginjectableantipsychoticsforfirstepisodeschizophreniatheprosandcons AT leesanghyuk longactinginjectableantipsychoticsforfirstepisodeschizophreniatheprosandcons AT yangyenkuang longactinginjectableantipsychoticsforfirstepisodeschizophreniatheprosandcons AT parkjongil longactinginjectableantipsychoticsforfirstepisodeschizophreniatheprosandcons AT chungyoungchul longactinginjectableantipsychoticsforfirstepisodeschizophreniatheprosandcons |